Exploration of a Potential DOOR Endpoint for Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs
Clinical Infectious Diseases · 19.07.2024 · 79 (1) · 60-69
DOI: 10.1093/cid/ciae163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 25.03.2024. Verfasst von Tori Kinamon und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: Pneumonia, Ventilator-Associated, Anti-Bacterial Agents, Pneumonia, Bacterial. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH, ARLG).
Abstract (Originalsprache)
Background
Desirability of outcome ranking (DOOR) is an innovative approach to clinical trial design and analysis that uses an ordinal ranking system to incorporate the overall risks and benefits of a therapeutic intervention into a single measurement. Here we derived and evaluated a disease-specific DOOR endpoint for registrational trials for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).
Methods
Through comprehensive examination of data from nearly 4000 participants enrolled in six registrational trials for HABP/VABP submitted to the Food and Drug Administration (FDA) between 2005 and 2022, we derived and applied a HABP/VABP specific endpoint. We estimated the probability that a participant assigned to the study treatment arm would have a more favorable overall DOOR or component outcome than a participant assigned to comparator.
Results
DOOR distributions between treatment arms were similar in all trials. DOOR probability estimates ranged from 48.3% to 52.9% and were not statistically different. There were no significant differences between treatment arms in the component analyses. Although infectious complications and serious adverse events occurred more frequently in ventilated participants compared to non-ventilated participants, the types of events were similar.
Conclusions
Through a data-driven approach, we constructed and applied a potential DOOR endpoint for HABP/VABP trials. The inclusion of syndrome-specific events may help to better delineate and evaluate participant experiences and outcomes in future HABP/VABP trials and could help inform data collection and trial design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
- Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
- Oak Ridge Institute for Science and Education, United States Department of Energy, Oak Ridge, Tennessee, USA.
- Patient Advocates in Research, Danville, California, USA.
- Department of Medicine, Division of Infectious Diseases, University of California San Francisco, San Francisco, California, USA.
- Biostatistics Center and Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Washington D.C., USA.
ORCID-Profile: Ursula Waack, Sarah B Doernberg, Scott R Evans
Förderung
- NIAID NIH HHS
- NIH
- ARLG)
- FDA
- Basilea Pharmaceutica
- NIAID
- Antibacterial Resistance Leadership Group
Zitieren
APA
Kinamon, T., Waack, U., Needles, M., Rubin, D., Collyar, D., Doernberg, S. B., Evans, S. R., Hamasaki, T., Holland, T. L., Howard-Anderson, J., Chambers, H., Fowler, V. G., Nambiar, S., Kim, P., Boucher, H. W., & Gopinath, R. (2024). Exploration of a Potential DOOR Endpoint for Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs. Clinical Infectious Diseases, 79(1), 60-69. https://doi.org/10.1093/cid/ciae163
Vancouver
Kinamon T, Waack U, Needles M, Rubin D, Collyar D, Doernberg SB, et al. Exploration of a Potential DOOR Endpoint for Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs. Clinical Infectious Diseases. 2024;79(1):60-69. doi:10.1093/cid/ciae163
BibTeX
@article{Kinamon2024,
author = {Kinamon, Tori and Waack, Ursula and Needles, Mark and Rubin, Daniel and Collyar, Deborah and Doernberg, Sarah B and Evans, Scott R and Hamasaki, Toshimitsu and Holland, Thomas L and Howard-Anderson, Jessica and Chambers, Henry and Fowler, Vance G and Nambiar, Sumati and Kim, Peter and Boucher, Helen W and Gopinath, Ramya},
title = {Exploration of a Potential DOOR Endpoint for Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs},
journal = {Clinical Infectious Diseases},
year = {2024},
volume = {79},
number = {1},
pages = {60--69},
doi = {10.1093/cid/ciae163}
}
EUVIMED